Aldeyra The
Buy, Hold or Sell?
Let's analyze Aldeyra together
I guess you are interested in Aldeyra The. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.
I'm going to help you getting a better view of Aldeyra The. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.
Get notifications about Aldeyra The
I send you an email if I find something interesting about Aldeyra The.
1. Quick Overview
1.1. Quick analysis of Aldeyra (30 sec.)
1.2. What can you expect buying and holding a share of Aldeyra? (30 sec.)
How much money do you get?
What is your share worth?
+ What do you gain per year?
2. Detailed Analysis
2.1. Valuation of Aldeyra (5 min.)
2.2. Growth of Aldeyra (5 min.)
2.3. Financial Health of Aldeyra (5 min.)
2.4. Comparing to competitors in the Biotechnology industry (5 min.)
Industry Rankings (Biotechnology)
3. Summary and Key Metrics
3.1. What can you expect buying and holding a share of Aldeyra?
Welcome investor! Aldeyra's management wants to use your money to grow the business. In return you get a share of Aldeyra.
First you should know what it really means to hold a share of Aldeyra. And how you can make/lose money.
Speculation
The Price per Share of Aldeyra is $4.82. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.
If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:
- The fundamentals: the financial health trends of Aldeyra.
- The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
- The book value: what is the market price compared to it's book value.
Investing
If you really want to invest in Aldeyra, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:
- You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.43. Based on the TTM, the Book Value Change Per Share is $-0.16 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.16 per quarter.
- You may receive quarterly/yearly dividend in the form of additional shares.
- You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
How much money are you going to get?
MRQ | TTM | YOY | 5Y | 10Y | ||||||
---|---|---|---|---|---|---|---|---|---|---|
$ | % of Price per Share | $ | % of Price per Share | $ | % of Price per Share | $ | % of Price per Share | $ | % of Price per Share | |
Usd Eps | -0.25 | -5.3% | -0.19 | -3.9% | -0.19 | -4.0% | -0.21 | -4.3% | -0.16 | -3.4% |
Usd Book Value Change Per Share | -0.22 | -4.6% | -0.16 | -3.3% | -0.16 | -3.4% | 0.03 | 0.6% | 0.03 | 0.7% |
Usd Dividend Per Share | 0.00 | 0.0% | 0.00 | 0.1% | 0.00 | 0.0% | 0.00 | 0.0% | 0.00 | 0.0% |
Usd Total Gains Per Share | -0.22 | -4.6% | -0.15 | -3.2% | -0.16 | -3.4% | 0.03 | 0.6% | 0.03 | 0.7% |
Usd Price Per Share | 5.39 | - | 3.87 | - | 7.99 | - | 6.20 | - | 6.66 | - |
Price to Earnings Ratio | -5.31 | - | -6.31 | - | -10.89 | - | -8.03 | - | -14.86 | - |
Price-to-Total Gains Ratio | -24.29 | - | -41.04 | - | -51.44 | - | -30.52 | - | -26.87 | - |
Price to Book Ratio | 3.77 | - | 2.31 | - | 3.53 | - | 3.43 | - | 10.01 | - |
Price-to-Total Gains Ratio | -24.29 | - | -41.04 | - | -51.44 | - | -30.52 | - | -26.87 | - |
When do you get the money?
Usd Investment | |
---|---|
Usd Price Per Share | 4.82 |
Number of shares | 207 |
Gains per Quarter | Trailing 12 Months | 5 Year |
---|---|---|
Usd Dividend Per Share | 0.00 | 0.00 |
Usd Book Value Change Per Share | -0.16 | 0.03 |
Usd Total Gains Per Share | -0.15 | 0.03 |
Gains per Quarter (207 shares) | -32.04 | 6.13 |
Gains per Year (207 shares) | -128.16 | 24.51 |
Years | Return on Investment (TTM) | Return on Investment (5Y) | ||||
---|---|---|---|---|---|---|
Dividend | Book Value gain | Total gains | Dividend | Book Value gain | Total gains | |
Broker costs | - | - | -10 | - | - | -10 |
1 | 4 | -132 | -138 | 1 | 24 | 15 |
2 | 7 | -264 | -266 | 1 | 48 | 40 |
3 | 11 | -395 | -394 | 2 | 71 | 65 |
4 | 14 | -527 | -522 | 3 | 95 | 90 |
5 | 18 | -659 | -650 | 4 | 119 | 115 |
6 | 22 | -791 | -778 | 4 | 143 | 140 |
7 | 25 | -923 | -906 | 5 | 167 | 165 |
8 | 29 | -1054 | -1034 | 6 | 190 | 190 |
9 | 33 | -1186 | -1162 | 7 | 214 | 215 |
10 | 36 | -1318 | -1290 | 7 | 238 | 240 |
How sure are you?
Based on the past periods, how sure are you to get value out of your investment.
Linear %
Trailing 12 Months | 3Y | 5 Year | 10 Year | ALLTIME | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% | % | % | % | % | ||||||||||||||||
Earnings Per Share | 0.0 | 4.0 | 0.0 | 0.0% | 0.0 | 12.0 | 0.0 | 0.0% | 0.0 | 20.0 | 0.0 | 0.0% | 0.0 | 40.0 | 0.0 | 0.0% | 2.0 | 46.0 | 0.0 | 4.2% |
Book Value Change Per Share | 0.0 | 4.0 | 0.0 | 0.0% | 0.0 | 12.0 | 0.0 | 0.0% | 4.0 | 16.0 | 0.0 | 20.0% | 11.0 | 29.0 | 0.0 | 27.5% | 14.0 | 32.0 | 2.0 | 29.2% |
Dividend per Share | 1.0 | 0.0 | 3.0 | 25.0% | 1.0 | 0.0 | 11.0 | 8.3% | 1.0 | 0.0 | 19.0 | 5.0% | 1.0 | 0.0 | 39.0 | 2.5% | 1.0 | 0.0 | 47.0 | 2.1% |
Total Gains per Share | 0.0 | 4.0 | 0.0 | 0.0% | 0.0 | 12.0 | 0.0 | 0.0% | 4.0 | 16.0 | 0.0 | 20.0% | 11.0 | 29.0 | 0.0 | 27.5% | 14.0 | 32.0 | 2.0 | 29.2% |
3.2. Key Performance Indicators
The key performance indicators of Aldeyra The compared to the Most Recent Quarter (MRQ).
End of day | +/- | Most Recent Quarter | Trailing 12 Months | +/- | Year-Over-Year | +/- | 5 Year | +/- | 10 Year | +/- | |
---|---|---|---|---|---|---|---|---|---|---|---|
Book Value Change Per Share | - | - | -0.222 | -0.159 | -28% | -0.165 | -26% | 0.029 | -872% | 0.032 | -788% |
Book Value Per Share | - | - | 1.429 | 1.749 | -18% | 2.272 | -37% | 2.135 | -33% | 1.372 | +4% |
Current Ratio | - | - | 6.805 | 5.954 | +14% | 9.764 | -30% | 11.923 | -43% | 12.262 | -45% |
Debt To Asset Ratio | - | - | 0.275 | 0.221 | +24% | 0.170 | +61% | 0.194 | +41% | 0.165 | +67% |
Debt To Equity Ratio | - | - | 0.379 | 0.286 | +32% | 0.205 | +84% | 0.252 | +50% | 0.208 | +82% |
Dividend Per Share | - | - | - | 0.004 | -100% | - | 0% | 0.001 | -100% | 0.000 | -100% |
Eps | - | - | -0.254 | -0.188 | -26% | -0.192 | -24% | -0.208 | -18% | -0.164 | -35% |
Free Cash Flow Per Share | - | - | -0.134 | -0.129 | -4% | -0.176 | +32% | -0.176 | +31% | -0.134 | 0% |
Free Cash Flow To Equity Per Share | - | - | -0.137 | -0.134 | -3% | -0.178 | +29% | 163306.078 | -100% | 81653.067 | -100% |
Gross Profit Margin | - | - | 1.000 | 1.093 | -9% | 1.000 | 0% | 1.019 | -2% | 1.009 | -1% |
Intrinsic Value_10Y_max | - | - | -4.182 | - | - | - | - | - | - | - | - |
Intrinsic Value_10Y_min | - | - | -7.049 | - | - | - | - | - | - | - | - |
Intrinsic Value_1Y_max | - | - | -0.519 | - | - | - | - | - | - | - | - |
Intrinsic Value_1Y_min | - | - | -0.727 | - | - | - | - | - | - | - | - |
Intrinsic Value_3Y_max | - | - | -1.483 | - | - | - | - | - | - | - | - |
Intrinsic Value_3Y_min | - | - | -2.180 | - | - | - | - | - | - | - | - |
Intrinsic Value_5Y_max | - | - | -2.356 | - | - | - | - | - | - | - | - |
Intrinsic Value_5Y_min | - | - | -3.616 | - | - | - | - | - | - | - | - |
Market Cap | 287029072.000 | -12% | 320972344.000 | 230456952.000 | +39% | 475801304.000 | -33% | 368984209.000 | -13% | 396369581.300 | -19% |
Net Profit Margin | - | - | - | -3.026 | 0% | - | 0% | -0.605 | 0% | 0.044 | -100% |
Operating Margin | - | - | - | -2.699 | 0% | - | 0% | -0.540 | 0% | 0.074 | -100% |
Operating Ratio | - | - | - | 3.883 | -100% | - | 0% | 0.777 | -100% | 0.043 | -100% |
Pb Ratio | 3.373 | -12% | 3.772 | 2.310 | +63% | 3.533 | +7% | 3.433 | +10% | 10.011 | -62% |
Pe Ratio | -4.748 | +11% | -5.310 | -6.313 | +19% | -10.886 | +105% | -8.029 | +51% | -14.864 | +180% |
Price Per Share | 4.820 | -12% | 5.390 | 3.870 | +39% | 7.990 | -33% | 6.196 | -13% | 6.656 | -19% |
Price To Free Cash Flow Ratio | -8.998 | +11% | -10.062 | 21.437 | -147% | -11.659 | +16% | -3.797 | -62% | -15.717 | +56% |
Price To Total Gains Ratio | -21.721 | +11% | -24.289 | -41.042 | +69% | -51.438 | +112% | -30.523 | +26% | -26.869 | +11% |
Quick Ratio | - | - | 6.842 | 6.738 | +2% | 10.041 | -32% | 16.069 | -57% | 16.879 | -59% |
Return On Assets | - | - | -0.129 | -0.088 | -32% | -0.067 | -48% | -0.090 | -30% | -0.132 | +2% |
Return On Equity | - | - | -0.178 | -0.115 | -35% | -0.081 | -54% | -0.116 | -34% | -0.162 | -9% |
Total Gains Per Share | - | - | -0.222 | -0.155 | -30% | -0.165 | -26% | 0.030 | -850% | 0.033 | -779% |
Usd Book Value | - | - | 85095704.000 | 104155128.500 | -18% | 135285545.000 | -37% | 127142871.150 | -33% | 81679019.000 | +4% |
Usd Book Value Change Per Share | - | - | -0.222 | -0.159 | -28% | -0.165 | -26% | 0.029 | -872% | 0.032 | -788% |
Usd Book Value Per Share | - | - | 1.429 | 1.749 | -18% | 2.272 | -37% | 2.135 | -33% | 1.372 | +4% |
Usd Dividend Per Share | - | - | - | 0.004 | -100% | - | 0% | 0.001 | -100% | 0.000 | -100% |
Usd Eps | - | - | -0.254 | -0.188 | -26% | -0.192 | -24% | -0.208 | -18% | -0.164 | -35% |
Usd Free Cash Flow | - | - | -7974915.000 | -7667865.500 | -4% | -10510357.000 | +32% | -10470068.650 | +31% | -7965265.550 | 0% |
Usd Free Cash Flow Per Share | - | - | -0.134 | -0.129 | -4% | -0.176 | +32% | -0.176 | +31% | -0.134 | 0% |
Usd Free Cash Flow To Equity Per Share | - | - | -0.137 | -0.134 | -3% | -0.178 | +29% | 163306.078 | -100% | 81653.067 | -100% |
Usd Market Cap | 287029072.000 | -12% | 320972344.000 | 230456952.000 | +39% | 475801304.000 | -33% | 368984209.000 | -13% | 396369581.300 | -19% |
Usd Price Per Share | 4.820 | -12% | 5.390 | 3.870 | +39% | 7.990 | -33% | 6.196 | -13% | 6.656 | -19% |
Usd Profit | - | - | -15112983.000 | -11198909.750 | -26% | -11050192.750 | -27% | -12337439.350 | -18% | -9722012.550 | -36% |
Usd Revenue | - | - | - | 98155.000 | -100% | - | 0% | 19631.000 | -100% | 603043588914.350 | -100% |
Usd Total Gains Per Share | - | - | -0.222 | -0.155 | -30% | -0.165 | -26% | 0.030 | -850% | 0.033 | -779% |
EOD | +3 -5 | MRQ | TTM | +8 -26 | YOY | +7 -22 | 5Y | +7 -27 | 10Y | +8 -28 |
3.3 Fundamental Score
Penke's Stock Scanner
Indicator | Condition | Value | ||
---|---|---|---|---|
Price to Earnings Ratio (EOD) | Between | 0-15 | -4.748 | |
Price to Book Ratio (EOD) | Between | 0-1 | 3.373 | |
Net Profit Margin (MRQ) | Greater than | 0 | 0.000 | |
Operating Margin (MRQ) | Greater than | 0 | 0.000 | |
Quick Ratio (MRQ) | Greater than | 1 | 6.842 | |
Current Ratio (MRQ) | Greater than | 1 | 6.805 | |
Debt to Asset Ratio (MRQ) | Less than | 1 | 0.275 | |
Debt to Equity Ratio (MRQ) | Less than | 1 | 0.379 | |
Return on Equity (MRQ) | Greater than | 0.15 | -0.178 | |
Return on Assets (MRQ) | Greater than | 0.05 | -0.129 | |
Total | 4/10 (40.0%) |
3.4 Technical Score
Penke's Symbol Scanner
Indicator | Condition | Value | ||
---|---|---|---|---|
Rsi | Greater than | 50 | 44.914 | |
Ma 20 | Greater than | Ma 50 | 4.915 | |
Ma 50 | Greater than | Ma 100 | 5.221 | |
Ma 100 | Greater than | Ma 200 | 5.061 | |
Open | Greater than | Close | 4.910 | |
Total | 3/5 (60.0%) |
4. In-depth Analysis
4.1 About Aldeyra The
- https://www.aldeyra.com
- Biotechnology
- 9
- 131 Hartwell Avenue, Lexington, MA, United States, 02421
Google Maps Bing Maps
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Fundamental data was last updated by Penke on 2024-11-14 09:36:03.
4.2 In-depth Summary
4.2.1. Financial Health Summary
Compared to previous year | Compared to industry | |
---|---|---|
The company is making a huge loss. | ||
Using its assets, the company is very inefficient in making profit. | ||
Using its investors money, the company is very inefficient in making profit. |
Compared to previous year | Compared to industry | |
---|---|---|
The company is operating very inefficient. | ||
The company is inefficient in keeping operating costs low. |
Compared to previous year | Compared to industry | |
---|---|---|
The company is very able to pay all its short-term debts. | ||
The company is very able to pay all its short-term debts with the most liquid assets. |
Compared to previous year | Compared to industry | |
---|---|---|
The company is very able to pay all its debts by selling its assets. | ||
The company is very able to pay all its debts with equity. |
4.2.2. Valuation Summary
Compared to previous year | Compared to industry | |
---|---|---|
Based on the equity, the company is underpriced. | ||
Based on the earnings, the company is expensive. | ||
Based on how much money comes from the company's main activities, the company is underpriced. |
4.3 Financial Health
4.3.1. Profitability
4.3.1 Profitability
4.3.1.1. Net Profit Margin
- Above 10% is considered healthy but always compare Aldeyra to the Biotechnology industry mean.
- A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.
Let's take a look of the Net Profit Margin trends of Aldeyra The:
- The MRQ is 0.0%. The data is not here.
Trends
- The 5Y is -60.5%. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is 4.4%. Compared to the 5Y term, the 10Y term is trending down. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | - | TTM | -302.6% | +302.6% | |
TTM | -302.6% | YOY | - | -302.6% | |
TTM | -302.6% | 5Y | -60.5% | -242.1% | |
5Y | -60.5% | 10Y | 4.4% | -64.9% |
Compared to industry (Biotechnology)
Let compare the company's Net Profit Margin with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -112.2%. trending up. +2
- The TTM average (mean) in the Biotechnology industry is -221.4%. trending down. -2
4.3.1.2. Return on Assets
- Above 5% is considered healthy but always compare Aldeyra to the Biotechnology industry mean.
- -12.9% Return on Assets means that Aldeyra generated $-0.13 profit for each $1 in assets.
Let's take a look of the Return on Assets trends of Aldeyra The:
Trends
- The YOY is -6.7%. Compared to the TTM, the mid term is trending down. -2
- The 5Y is -9.0%. Compared to the TTM, the 5Y term is trending up. +2
- The 10Y is -13.2%. Compared to the 5Y term, the 10Y term is trending up. +2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | -12.9% | TTM | -8.8% | -4.1% | |
TTM | -8.8% | YOY | -6.7% | -2.1% | |
TTM | -8.8% | 5Y | -9.0% | +0.2% | |
5Y | -9.0% | 10Y | -13.2% | +4.2% |
Compared to industry (Biotechnology)
Let compare the company's Return on Assets with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -11.3%. trending down. -2
- The TTM average (mean) in the Biotechnology industry is -11.7%. trending up. +2
4.3.1.3. Return on Equity
- Above 15%-20% is considered healthy but always compare Aldeyra to the Biotechnology industry mean.
- -17.8% Return on Equity means Aldeyra generated $-0.18 for each $1 the owners (shareholders) invested.
Let's take a look of the Return on Equity trends of Aldeyra The:
Trends
- The YOY is -8.1%. Compared to the TTM, the mid term is trending down. -2
- The 5Y is -11.6%. Compared to the TTM, the 5Y term is trending up. +2
- The 10Y is -16.2%. Compared to the 5Y term, the 10Y term is trending up. +2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | -17.8% | TTM | -11.5% | -6.3% | |
TTM | -11.5% | YOY | -8.1% | -3.4% | |
TTM | -11.5% | 5Y | -11.6% | +0.1% | |
5Y | -11.6% | 10Y | -16.2% | +4.5% |
Compared to industry (Biotechnology)
Let compare the company's Return on Equity with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -14.2%. trending down. -2
- The TTM average (mean) in the Biotechnology industry is -15.9%. trending up. +2
4.3.2. Operating Efficiency of Aldeyra The.
4.3.2. Operating Efficiency
4.3.2.1. Operating Margin
- Measures how much profit Aldeyra makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
- Above 15% is considered healthy but always compare Aldeyra to the Biotechnology industry mean.
- An Operating Margin of 0.0% means the company generated $0.00 for each $1 in revenue (before taxes).
Let's take a look of the Operating Margin trends of Aldeyra The:
- The MRQ is 0.0%. The data is not here.
Trends
- The 5Y is -54.0%. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is 7.4%. Compared to the 5Y term, the 10Y term is trending down. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | - | TTM | -269.9% | +269.9% | |
TTM | -269.9% | YOY | - | -269.9% | |
TTM | -269.9% | 5Y | -54.0% | -215.9% | |
5Y | -54.0% | 10Y | 7.4% | -61.4% |
Compared to industry (Biotechnology)
Let compare the company's Operating Margin with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -222.9%. trending up. +2
- The TTM average (mean) in the Biotechnology industry is -310.7%. trending up. +2
4.3.2.2. Operating Ratio
- Below 1 is considered healthy (always compare to Biotechnology industry mean).
- An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.
Let's take a look of the Operating Ratio trends of Aldeyra The:
- The MRQ is 0.000. The data is not here.
Trends
- The 5Y is 0.777. Compared to the TTM, the 5Y term is trending up. -2
- The 10Y is 0.043. Compared to the 5Y term, the 10Y term is trending up. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | - | TTM | 3.883 | -3.883 | |
TTM | 3.883 | YOY | - | +3.883 | |
TTM | 3.883 | 5Y | 0.777 | +3.106 | |
5Y | 0.777 | 10Y | 0.043 | +0.733 |
Compared to industry (Biotechnology)
Let compare the company's Operating Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 2.465. trending down. +2
- The TTM average (mean) in the Biotechnology industry is 3.253. trending up. -2
4.4.3. Liquidity of Aldeyra The.
4.4.3. Liquidity
4.4.3.1. Current Ratio
- Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
- A Current Ratio of 6.80 means the company has $6.80 in assets for each $1 in short-term debts.
Let's take a look of the Current Ratio trends of Aldeyra The:
Trends
- The YOY is 9.764. Compared to the TTM, the mid term is trending down. -2
- The 5Y is 11.923. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is 12.262. Compared to the 5Y term, the 10Y term is trending down. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 6.805 | TTM | 5.954 | +0.850 | |
TTM | 5.954 | YOY | 9.764 | -3.809 | |
TTM | 5.954 | 5Y | 11.923 | -5.969 | |
5Y | 11.923 | 10Y | 12.262 | -0.338 |
Compared to industry (Biotechnology)
Let compare the company's Current Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 3.637. trending up. +2
- The TTM average (mean) in the Biotechnology industry is 3.890. trending up. +2
4.4.3.2. Quick Ratio
- Above 1 is considered healthy but always compare Aldeyra to the Biotechnology industry mean.
- A Quick Ratio of 6.84 means the company can pay off $6.84 for each $1 in debt (using most liquid assets).
Let's take a look of the Quick Ratio trends of Aldeyra The:
Trends
- The YOY is 10.041. Compared to the TTM, the mid term is trending down. -2
- The 5Y is 16.069. Compared to the TTM, the 5Y term is trending down. -2
- The 10Y is 16.879. Compared to the 5Y term, the 10Y term is trending down. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 6.842 | TTM | 6.738 | +0.104 | |
TTM | 6.738 | YOY | 10.041 | -3.303 | |
TTM | 6.738 | 5Y | 16.069 | -9.331 | |
5Y | 16.069 | 10Y | 16.879 | -0.810 |
Compared to industry (Biotechnology)
Let compare the company's Quick Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 3.086. trending up. +2
- The TTM average (mean) in the Biotechnology industry is 3.451. trending up. +2
4.5.4. Solvency of Aldeyra The.
4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio
- Below 1 (100%) is considered healthy but always compare Aldeyra to Biotechnology industry mean.
- A Debt to Asset Ratio of 0.27 means that Aldeyra assets are financed with 27.5% credit (debt) and the remaining percentage (100% - 27.5%) is financed by its owners/shareholders.
Let's take a look of the Debt to Asset Ratio trends of Aldeyra The:
Trends
- The YOY is 0.170. Compared to the TTM, the mid term is trending up. -2
- The 5Y is 0.194. Compared to the TTM, the 5Y term is trending up. -2
- The 10Y is 0.165. Compared to the 5Y term, the 10Y term is trending up. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 0.275 | TTM | 0.221 | +0.054 | |
TTM | 0.221 | YOY | 0.170 | +0.051 | |
TTM | 0.221 | 5Y | 0.194 | +0.027 | |
5Y | 0.194 | 10Y | 0.165 | +0.030 |
Compared to industry (Biotechnology)
Let compare the company's Debt to Asset Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 0.350. trending down. +2
- The TTM average (mean) in the Biotechnology industry is 0.344. trending down. +2
4.5.4.2. Debt to Equity Ratio
- Below 2 is considered healthy but always compare Aldeyra to the Biotechnology industry mean.
- A Debt to Equity ratio of 37.9% means that company has $0.38 debt for each $1 in shareholders equity.
Let's take a look of the Debt to Equity Ratio trends of Aldeyra The:
Trends
- The YOY is 0.205. Compared to the TTM, the mid term is trending up. -2
- The 5Y is 0.252. Compared to the TTM, the 5Y term is trending up. -2
- The 10Y is 0.208. Compared to the 5Y term, the 10Y term is trending up. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
MRQ | 0.379 | TTM | 0.286 | +0.092 | |
TTM | 0.286 | YOY | 0.205 | +0.081 | |
TTM | 0.286 | 5Y | 0.252 | +0.034 | |
5Y | 0.252 | 10Y | 0.208 | +0.044 |
Compared to industry (Biotechnology)
Let compare the company's Debt to Equity Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 0.394. trending down. +2
- The TTM average (mean) in the Biotechnology industry is 0.432. trending down. +2
4.6. Market Valuation
4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio
- Above 15 is considered overpriced but always compare Aldeyra to the Biotechnology industry mean.
- A PE ratio of -5.31 means the investor is paying $-5.31 for every $1 in earnings.
Let's take a look of the Price to Earnings Ratio trends of Aldeyra The:
Trends
- The YOY is -10.886. Compared to the TTM, the mid term is trending up. -2
- The 5Y is -8.029. Compared to the TTM, the 5Y term is trending up. -2
- The 10Y is -14.864. Compared to the 5Y term, the 10Y term is trending up. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
EOD | -4.748 | MRQ | -5.310 | +0.561 | |
MRQ | -5.310 | TTM | -6.313 | +1.003 | |
TTM | -6.313 | YOY | -10.886 | +4.573 | |
TTM | -6.313 | 5Y | -8.029 | +1.716 | |
5Y | -8.029 | 10Y | -14.864 | +6.835 |
Compared to industry (Biotechnology)
Let compare the company's Price to Earnings Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -2.403. trending down. +2
- The TTM average (mean) in the Biotechnology industry is -3.148. trending down. +2
4.6.2.2. Price To Free Cash Flow Ratio
Let's take a look of the Price To Free Cash Flow Ratio trends of Aldeyra The:
- The EOD is -8.998. Based on how much money comes from the company's main activities, the company is expensive. -2
- The MRQ is -10.062. Based on how much money comes from the company's main activities, the company is expensive. -2
- The TTM is 21.437. Based on how much money comes from the company's main activities, the company is underpriced. +1
Trends
- The YOY is -11.659. Compared to the TTM, the mid term is trending up. +2
- The 5Y is -3.797. Compared to the TTM, the 5Y term is trending up. +2
- The 10Y is -15.717. Compared to the 5Y term, the 10Y term is trending up. -2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
EOD | -8.998 | MRQ | -10.062 | +1.064 | |
MRQ | -10.062 | TTM | 21.437 | -31.499 | |
TTM | 21.437 | YOY | -11.659 | +33.096 | |
TTM | 21.437 | 5Y | -3.797 | +25.234 | |
5Y | -3.797 | 10Y | -15.717 | +11.920 |
Compared to industry (Biotechnology)
Let compare the company's priceToFreeCashFlowRatio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is -3.234. trending down. +2
- The TTM average (mean) in the Biotechnology industry is -3.719. trending up. +2
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio
- At or below 1 is considered healthy (always compare to Biotechnology industry mean).
- A PB ratio of 3.77 means the investor is paying $3.77 for each $1 in book value.
Let's take a look of the Price to Book Ratio trends of Aldeyra The:
Trends
- The YOY is 3.533. Compared to the TTM, the mid term is trending down. +2
- The 5Y is 3.433. Compared to the TTM, the 5Y term is trending down. +2
- The 10Y is 10.011. Compared to the 5Y term, the 10Y term is trending down. +2
Current period | Compared to | +/- | |||
---|---|---|---|---|---|
EOD | 3.373 | MRQ | 3.772 | -0.399 | |
MRQ | 3.772 | TTM | 2.310 | +1.462 | |
TTM | 2.310 | YOY | 3.533 | -1.224 | |
TTM | 2.310 | 5Y | 3.433 | -1.123 | |
5Y | 3.433 | 10Y | 10.011 | -6.578 |
Compared to industry (Biotechnology)
Let compare the company's Price to Book Ratio with the average (mean) in the Biotechnology industry:
- The MRQ average (mean) in the Biotechnology industry is 2.051. trending up. -2
- The TTM average (mean) in the Biotechnology industry is 2.356. trending down. +2
4.6.2. Total Gains per Share
4.7 Holders & Insider Transactions
Let's take a look at which institutions, funds and insiders are holding shares of Aldeyra The.
4.8.1. Institutions holding Aldeyra The
Institutions are holding 60.545% of the shares of Aldeyra The.
Date | Name | Total Shares | Total Assets | Current Shares | Change | % |
---|---|---|---|---|---|---|
2024-06-30 | Perceptive Advisors LLC | 15.6102 | 0.7395 | 9275851 | 682265 | 7.9392 |
2024-06-30 | Knoll Capital Management LP | 9.2147 | 12.2123 | 5475516 | 0 | 0 |
2024-06-30 | Vanguard Group Inc | 6.298 | 0.0002 | 3742386 | -126693 | -3.2745 |
2024-06-30 | BlackRock Inc | 6.0953 | 0.0003 | 3621949 | 311162 | 9.3984 |
2024-06-30 | Kennedy Capital Management Inc | 2.6921 | 0.1132 | 1599673 | 281518 | 21.357 |
2024-06-30 | Geode Capital Management, LLC | 1.9152 | 0.0003 | 1138043 | 109845 | 10.6833 |
2024-06-30 | State Street Corp | 1.6117 | 0.0001 | 957720 | 18151 | 1.9318 |
2024-06-30 | Eagle Asset Management, Inc. | 1.4163 | 0.0147 | 841571 | -126244 | -13.0442 |
2024-06-30 | Dimensional Fund Advisors, Inc. | 1.131 | 0.0006 | 672057 | -210153 | -23.8212 |
2024-06-30 | Morgan Stanley - Brokerage Accounts | 1.0481 | 0.0001 | 622808 | -76284 | -10.9119 |
2024-06-30 | Federated Hermes Inc | 0.894 | 0.0042 | 531221 | 531221 | 0 |
2024-06-30 | Renaissance Technologies Corp | 0.847 | 0.0028 | 503300 | -224390 | -30.8359 |
2024-06-30 | Wells Fargo & Co | 0.6652 | 0.0003 | 395297 | 7993 | 2.0638 |
2024-09-30 | PFG Investments, LLC | 0.6503 | 0.1345 | 386447 | -9800 | -2.4732 |
2024-06-30 | Northern Trust Corp | 0.6488 | 0.0002 | 385507 | -3680 | -0.9456 |
2024-06-30 | Bank of America Corp | 0.637 | 0.0001 | 378490 | -20461 | -5.1287 |
2024-06-30 | Los Angeles Capital Management LLC | 0.5632 | 0.004 | 334669 | -46104 | -12.108 |
2024-06-30 | D. E. Shaw & Co LP | 0.5418 | 0.001 | 321938 | -225702 | -41.2136 |
2024-06-30 | Deutsche Bank AG | 0.5055 | 0.0005 | 300352 | 7965 | 2.7241 |
2024-06-30 | Johnson & Johnson | 0.5043 | 0.2476 | 299669 | 0 | 0 |
Total | 53.4897 | 13.4765 | 31784464 | +880609 | +2.8% |
4.9.2. Funds holding Aldeyra The
Date | Name | Total Shares | Total Assets | Current Shares | Change | % |
---|---|---|---|---|---|---|
2024-09-30 | Vanguard Total Stock Mkt Idx Inv | 2.9597 | 0.0005 | 1758714 | 0 | 0 |
2024-10-31 | iShares Russell 2000 ETF | 2.1816 | 0.0101 | 1296318 | -2912 | -0.2241 |
2024-09-30 | Kennedy Micro Cap | 1.4465 | 0.946 | 859506 | -273368 | -24.1305 |
2024-09-30 | Vanguard Institutional Extnd Mkt Idx Tr | 1.1739 | 0.0035 | 697567 | -37474 | -5.0982 |
2024-09-30 | Vanguard Explorer Inv | 1.1444 | 0.0163 | 680004 | 0 | 0 |
2024-10-31 | Invesco Dorsey Wright SmallCap Momt ETF | 1.0672 | 0.3436 | 634120 | 0 | 0 |
2024-08-31 | Fidelity Small Cap Index | 0.8585 | 0.0108 | 510128 | -9967 | -1.9164 |
2024-10-31 | iShares Russell 2000 Value ETF | 0.6989 | 0.0177 | 415311 | 0 | 0 |
2024-09-30 | Eagle Small Cap Growth – Institutional | 0.6328 | 0.2229 | 376024 | -83480 | -18.1674 |
2024-10-31 | State St Russell Sm/Mid Cp® Indx NL Cl C | 0.5471 | 0.0038 | 325100 | -10200 | -3.0421 |
2024-09-30 | Federated Hermes MDT Small Cap Growth IS | 0.5388 | 0.3417 | 320145 | 17566 | 5.8054 |
2024-09-30 | Federated Hermes MDT SCG Institutional | 0.5388 | 0.3417 | 320145 | 17566 | 5.8054 |
2024-09-30 | Kennedy Extended Small Cap | 0.4926 | 0.141 | 292721 | 55368 | 23.3273 |
2024-09-30 | DWS ESG Biotech LC | 0.4494 | 0.3743 | 267070 | 1 | 0.0004 |
2024-09-30 | Fidelity Extended Market Index | 0.4254 | 0.0033 | 252763 | -24481 | -8.8301 |
2024-09-30 | Carillon Eagle Small Cap Growth A | 0.3949 | 0.2554 | 234668 | -30483 | -11.4965 |
2024-09-30 | Vanguard Russell 2000 ETF | 0.385 | 0.0099 | 228767 | 27930 | 13.9068 |
2024-09-30 | Federated Hermes MDT Small Cap Core IS | 0.3834 | 0.0882 | 227814 | 0 | 0 |
2024-09-30 | Federated Hermes MDT SCC Institutional | 0.3834 | 0.0882 | 227814 | 0 | 0 |
2024-09-30 | Kennedy Small Cap Select | 0.369 | 0.5149 | 219256 | 219256 | 0 |
Total | 17.0713 | 3.7338 | 10143955 | -134678 | -1.3% |
5.3. Insider Transactions
Insiders are holding 2.441% of the shares of Aldeyra The.
5. Financial Statements
5.1. Reversals in quarterly reports
I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.
2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | ||||||
---|---|---|---|---|---|---|---|---|---|---|
Interest Expense | 539 | -24 | 514 | -16 | 499 | -21 | 478 | -957 | -479 |
5.2. Latest Balance Sheet
Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.
Summary
As reported | |
---|---|
Total Liabilities | 32,224 |
Total Stockholder Equity | + 85,096 |
Total Assets | = 117,319 |
Assets
Total Current Assets
Long-term Assets
Property Plant Equipment | 331 |
Long-term Assets Other | 267 |
Long-term Assets (as reported) | 599 |
---|---|
Long-term Assets (calculated) | 599 |
+/- | 0 |
Liabilities & Shareholders' Equity
Total Current Liabilities
Long-term Liabilities
Long-term Liabilities (as reported) | 15,070 |
---|---|
Long-term Liabilities (calculated) | 0 |
+/- | 15,070 |
5.3. Balance Sheets Structured
Currency in USD. All numbers in thousands.
Trend | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-12-31 | 2014-09-30 | 2014-06-30 | 2014-03-31 | 2013-12-31 | 2013-09-30 | 2013-06-30 | 2013-03-31 | 2012-12-31 | |||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
> Total Assets |
| 117,319 | 126,044 | 141,302 | 148,327 | 147,282 | 155,616 | 168,219 | 181,292 | 189,692 | 201,015 | 222,693 | 233,137 | 247,218 | 256,427 | 147,306 | 83,353 | 88,324 | 71,627 | 63,029 | 75,518 | 77,441 | 73,839 | 88,128 | 95,091 | 37,132 | 43,286 | 40,776 | 44,175 | 49,229 | 26,468 | 31,532 | 25,188 | 29,191 | 32,884 | 23,437 | 28,205 | 31,350 | 33,878 | 15,931 | 8,787 | 10,351 | 11,805 | 2,891 | 3,743 | 2,819 | 0 | 0 | 1,977 | ||||||||||||||||||||||||||||||||||||||||||||||||
> Total Current Assets |
| 116,721 | 121,790 | 133,527 | 143,347 | 147,210 | 155,479 | 168,017 | 181,023 | 189,483 | 200,741 | 222,355 | 232,753 | 246,772 | 256,261 | 147,073 | 83,059 | 88,193 | 71,423 | 62,752 | 75,169 | 77,020 | 72,856 | 86,996 | 94,769 | 36,845 | 43,071 | 40,605 | 43,966 | 49,053 | 26,342 | 31,473 | 25,131 | 29,126 | 32,809 | 23,309 | 28,088 | 31,226 | 33,837 | 15,898 | 8,760 | 10,345 | 11,805 | 2,155 | 3,271 | 2,769 | 0 | 0 | 1,977 | ||||||||||||||||||||||||||||||||||||||||||||||||
Cash And Cash Equivalents |
| 28,120 | 31,030 | 52,492 | 142,823 | 143,335 | 151,676 | 165,028 | 144,419 | 128,651 | 121,012 | 158,909 | 229,791 | 241,369 | 249,739 | 138,442 | 77,858 | 86,176 | 60,689 | 38,543 | 44,426 | 51,604 | 39,400 | 44,298 | 47,357 | 18,009 | 24,606 | 20,964 | 20,023 | 33,104 | 14,610 | 19,303 | 12,015 | 14,569 | 17,608 | 10,149 | 14,649 | 30,618 | 33,570 | 15,721 | 8,527 | 10,142 | 11,536 | 2,146 | 3,262 | 2,764 | 0 | 0 | 1,224 | ||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Investments |
| 44,624 | 49,302 | 30,545 | 0 | 0 | 0 | 0 | 29,882 | 56,679 | 75,677 | 57,957 | 0 | 0 | 0 | 0 | 0 | 0 | 5,501 | 22,834 | 28,939 | 24,567 | 30,057 | 37,827 | 46,242 | 17,134 | 17,073 | 17,975 | 22,923 | 14,807 | 11,211 | 11,910 | 12,898 | 14,307 | 14,941 | 12,877 | 12,942 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||
Net Receivables |
| 0 | 40,000 | 50,000 | 0 | 0 | 0 | 24 | 3,242 | 21,500 | 79,000 | 65,000 | 125,000 | 125,000 | 125,000 | 50,000 | 25,000 | 15,000 | 10,000 | 23,000 | 28,000 | 26,000 | 32,000 | 39,000 | 44,000 | 11,000 | 17,000 | 0 | 18,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 750 | ||||||||||||||||||||||||||||||||||||||||||||||||
Other Current Assets |
| 43,977 | 46,354 | 490 | 524 | 212 | 259 | 2,989 | 6,722 | 4,154 | 328 | 433 | 558 | 870 | 1,297 | 216 | 407 | 2,017 | 5,233 | 1,375 | 1,804 | 849 | 3,399 | 4,872 | 1,170 | 1,703 | 1,393 | 1,667 | 1,019 | 1,142 | 521 | 261 | 219 | 250 | 260 | 284 | 498 | 607 | 267 | 177 | 233 | 203 | 270 | 10 | 8 | 4 | 0 | 0 | 3 | ||||||||||||||||||||||||||||||||||||||||||||||||
> Long-term Assets |
| 599 | 4,254 | 7,774 | 4,980 | 72 | 137 | 202 | 269 | 209 | 274 | 338 | 384 | 446 | 166 | 233 | 293 | 132 | 205 | 277 | 349 | 421 | 983 | 1,132 | 322 | 286 | 215 | 171 | 209 | 177 | 126 | 58 | 56 | 66 | 75 | 127 | 117 | 125 | 41 | 33 | 27 | 6 | 0 | 735 | 472 | 50 | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||
Property Plant Equipment |
| 331 | 394 | 456 | 517 | 72 | 137 | 202 | 269 | 209 | 274 | 338 | 384 | 446 | 166 | 233 | 293 | 132 | 205 | 277 | 349 | 421 | 491 | 594 | 235 | 243 | 215 | 171 | 43 | 38 | 48 | 58 | 56 | 66 | 75 | 81 | 80 | 88 | 41 | 13 | 13 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||
Other Assets |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 492 | 538 | 87 | 43 | 0 | 0 | 166 | 138 | 78 | 0 | 0 | 0 | 0 | 46 | 36 | 36 | 0 | 20 | 14 | 0 | 0 | 736 | 472 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||
> Total Liabilities |
| 32,224 | 27,733 | 27,882 | 28,532 | 24,275 | 25,733 | 30,976 | 30,284 | 27,498 | 26,986 | 32,004 | 27,402 | 27,548 | 22,747 | 21,232 | 23,844 | 19,154 | 18,838 | 19,557 | 27,436 | 26,562 | 6,506 | 9,648 | 8,473 | 8,537 | 6,305 | 4,775 | 4,574 | 3,324 | 3,128 | 3,537 | 3,538 | 3,520 | 3,366 | 2,910 | 3,326 | 2,655 | 2,353 | 2,105 | 2,503 | 2,087 | 1,990 | 4,027 | 2,128 | 14,583 | 0 | 0 | 27,132 | ||||||||||||||||||||||||||||||||||||||||||||||||
> Total Current Liabilities |
| 17,153 | 27,595 | 21,676 | 22,260 | 21,617 | 15,605 | 16,008 | 15,361 | 24,195 | 16,243 | 16,354 | 11,773 | 11,942 | 7,409 | 11,091 | 12,409 | 6,461 | 4,920 | 4,887 | 12,908 | 12,116 | 6,390 | 9,492 | 8,473 | 7,654 | 5,310 | 3,667 | 3,354 | 2,419 | 2,112 | 2,409 | 2,299 | 2,637 | 2,373 | 1,808 | 2,115 | 1,374 | 1,391 | 1,036 | 1,328 | 846 | 1,175 | 692 | 605 | 201 | 0 | 0 | 363 | ||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Debt |
| 543 | 15,752 | 15,452 | 15,625 | 13,527 | 6,024 | 1,145 | 1,161 | 12,634 | 5,168 | 236 | 230 | 222 | 118 | 5,271 | 3,893 | 2,318 | 1,010 | 172 | 226 | 219 | 212 | 221 | 0 | 465 | 349 | 233 | 116 | 427 | 310 | 194 | 78 | 427 | 310 | 194 | 78 | 0 | 310 | 194 | 78 | 0 | 407 | 388 | 143 | 0 | 0 | 0 | 167 | ||||||||||||||||||||||||||||||||||||||||||||||||
Short Long Term Debt |
| 0 | 15,242 | 15,205 | 15,147 | 13,461 | 5,894 | 954 | 912 | 12,449 | 4,926 | 0 | 0 | 0 | 0 | 5,095 | 3,660 | 2,259 | 894 | 0 | 0 | 0 | 0 | 221 | 0 | 465 | 349 | 233 | 116 | 427 | 1,327 | 194 | 78 | 0 | 0 | 0 | 78 | 0 | 0 | 0 | 78 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||
Accounts payable |
| 187 | 254 | 280 | 1,338 | 247 | 271 | 430 | 134 | 1,307 | 264 | 2,443 | 1,020 | 468 | 1,094 | 449 | 382 | 124 | 217 | 1,073 | 808 | 572 | 2,774 | 4,013 | 3,052 | 3,442 | 802 | 1,619 | 1,001 | 485 | 763 | 695 | 275 | 734 | 823 | 578 | 851 | 744 | 629 | 406 | 341 | 482 | 556 | 166 | 342 | 65 | 0 | 0 | 73 | ||||||||||||||||||||||||||||||||||||||||||||||||
Other Current Liabilities |
| 10,423 | 5,588 | 5,944 | 5,297 | 7,843 | 9,310 | 14,434 | 14,066 | 10,254 | 10,810 | 13,676 | 10,523 | 11,252 | 6,196 | 5,372 | 8,135 | 4,019 | 3,694 | 3,642 | 11,873 | 11,325 | 3,404 | 5,257 | 5,421 | 3,746 | 4,159 | 1,815 | 2,236 | 1,507 | 1,039 | 1,520 | 1,946 | 1,477 | 1,240 | 1,036 | 1,186 | 630 | 452 | 436 | 909 | 364 | 211 | 138 | 120 | 136 | 0 | 0 | 124 | ||||||||||||||||||||||||||||||||||||||||||||||||
> Long-term Liabilities |
| 15,070 | 139 | 6,206 | 6,272 | 2,657 | 10,128 | 14,968 | 14,923 | 3,303 | 10,744 | 15,650 | 15,629 | 15,606 | 15,338 | 10,141 | 11,434 | 12,693 | 13,917 | 14,670 | 14,528 | 14,445 | 116 | 157 | 0 | 883 | 995 | 1,108 | 1,220 | 905 | 1,016 | 1,128 | 1,239 | 883 | 993 | 1,102 | 1,211 | 1,281 | 962 | 1,069 | 1,175 | 1,241 | 816 | 3,336 | 1,523 | 14,382 | 0 | 0 | 26,768 | ||||||||||||||||||||||||||||||||||||||||||||||||
Long term Debt Total |
| 0 | 0 | 0 | 0 | 0 | 0 | 14,968 | 14,923 | 3,303 | 10,744 | 15,587 | 15,504 | 15,421 | 15,338 | 10,141 | 11,434 | 12,693 | 13,917 | 14,670 | 14,528 | 14,387 | 0 | 0 | 0 | 883 | 995 | 1,108 | 1,220 | 905 | 1,016 | 1,128 | 1,239 | 883 | 993 | 1,102 | 1,211 | 1,281 | 962 | 1,069 | 1,175 | 1,241 | 816 | 972 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||
Long term Debt |
| 0 | 0 | 0 | 0 | 2,657 | 10,128 | 14,968 | 14,923 | 3,303 | 10,744 | 15,587 | 15,504 | 15,421 | 15,338 | 10,141 | 11,434 | 12,693 | 13,917 | 14,670 | 14,528 | 14,387 | 0 | 157 | 0 | 883 | 995 | 1,108 | 1,220 | 905 | 1,016 | 1,128 | 1,239 | 883 | 993 | 1,102 | 1,211 | 1,281 | 962 | 1,069 | 1,175 | 1,241 | 816 | 972 | 4,648 | 0 | 0 | 0 | 2,535 | ||||||||||||||||||||||||||||||||||||||||||||||||
Capital Lease Obligations |
| 0 | 394 | 453 | 511 | 66 | 130 | 190 | 249 | 185 | 243 | 299 | 355 | 407 | 118 | 176 | 233 | 59 | 116 | 172 | 226 | 278 | 328 | 378 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||
Warrants |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 77,018 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||
Other Liabilities |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 604 | 394 | 0 | 0 | 0 | 24,234 | ||||||||||||||||||||||||||||||||||||||||||||||||
Long-term Liabilities Other |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 63 | 125 | 185 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 59 | 116 | 157 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2,231 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||
Deferred Long Term Liability |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 492 | 538 | 87 | 43 | 0 | 0 | 166 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 36 | 0 | 0 | 0 | 14 | 0 | 0 | 132 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||
> Total Stockholder Equity |
| 85,096 | 98,310 | 113,419 | 119,795 | 123,008 | 129,883 | 137,243 | 151,008 | 162,194 | 174,029 | 190,689 | 205,736 | 219,670 | 233,680 | 126,074 | 59,509 | 69,170 | 52,790 | 43,473 | 48,082 | 50,879 | 67,333 | 78,480 | 86,618 | 28,595 | 36,981 | 36,001 | 39,601 | 45,905 | 23,340 | 27,995 | 21,650 | 25,672 | 29,518 | 20,527 | 24,878 | 28,695 | 31,525 | 13,827 | 6,284 | 8,264 | 9,815 | -1,137 | 1,615 | -11,764 | 0 | 0 | -25,155 | ||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock |
| 60 | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 58 | 58 | 58 | 58 | 58 | 48 | 39 | 39 | 33 | 30 | 29 | 27 | 27 | 27 | 26 | 21 | 21 | 20 | 19 | 19 | 15 | 15 | 13 | 13 | 12 | 10 | 10 | 10 | 10 | 7 | 6 | 6 | 6 | 0 | 4 | 4 | 0 | 0 | 4 | ||||||||||||||||||||||||||||||||||||||||||||||||
Retained Earnings Total Equity |
| 0 | 0 | 0 | 0 | 0 | 0 | -372,332 | -356,717 | -343,814 | -329,261 | -311,480 | -294,692 | -278,937 | -263,143 | -248,206 | -236,916 | -225,624 | -216,750 | -209,230 | -199,362 | -186,201 | -167,486 | -154,159 | -138,535 | -127,902 | -117,089 | -108,039 | -99,642 | -92,687 | -87,701 | -82,392 | -77,301 | -72,650 | -67,872 | -63,569 | -58,602 | -54,246 | -50,880 | -48,648 | -46,512 | -44,067 | -42,058 | 40,923 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Income |
| 67 | -10 | -3 | 0 | 0 | 0 | 0 | -104 | -286 | -286 | -62 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 58 | 6 | 6 | 13 | 7 | -9 | -5 | -3 | -16 | -18 | -1 | -5 | -5 | 0 | 7 | 5 | 2 | -8 | 0 | 0 | 0 | 0 | -10,351 | -11,805 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||
Capital Surplus |
| 0 | 0 | 0 | 0 | 0 | 0 | 509,517 | 507,770 | 506,235 | 503,518 | 502,172 | 500,369 | 498,549 | 496,764 | 374,232 | 296,386 | 294,755 | 269,502 | 252,616 | 247,410 | 237,048 | 234,779 | 232,605 | 225,136 | 156,481 | 154,052 | 144,037 | 139,242 | 138,574 | 111,031 | 110,377 | 98,938 | 98,302 | 97,372 | 84,085 | 83,479 | 82,932 | 82,395 | 62,468 | 52,790 | 52,325 | 51,867 | 1,277 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||
Other Stockholders Equity |
| 519,271 | 517,449 | 515,704 | 513,995 | 512,455 | 511,144 | 509,517 | 507,770 | 506,235 | 503,518 | 502,172 | 500,369 | 498,549 | 496,764 | 374,232 | 296,386 | 294,755 | 269,502 | 252,616 | 247,410 | 237,048 | 234,779 | 232,605 | 225,136 | 156,481 | 154,052 | 144,037 | 139,242 | 138,574 | 111,031 | 110,377 | 98,938 | 98,302 | 97,372 | 84,085 | 83,479 | 82,932 | 82,395 | 62,468 | 52,790 | 52,325 | 51,867 | 1,277 | 42,935 | 897 | 0 | 0 | 0 |
5.4. Balance Sheets
Currency in USD. All numbers in thousands.
5.5. Cash Flows
Currency in USD. All numbers in thousands.